172 related articles for article (PubMed ID: 31106153)
1. Neoadjuvant Chemotherapy Alters Neuropilin-1, PlGF, and
Al-Zeheimi N; Naik A; Bakheit CS; Al Riyami M; Al Ajarrah A; Al Badi S; Al Baimani K; Malik K; Al Habsi Z; Al Moundhri MS; Adham SA
Front Oncol; 2019; 9():323. PubMed ID: 31106153
[TBL] [Abstract][Full Text] [Related]
2. Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study.
Naik A; Al-Zeheimi N; Bakheit CS; Al Riyami M; Al Jarrah A; Al Moundhri MS; Al Habsi Z; Basheer M; Adham SA
Sci Rep; 2017 Jun; 7(1):3301. PubMed ID: 28607365
[TBL] [Abstract][Full Text] [Related]
3. Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype.
Al-Zeheimi N; Adham SA
Br J Pharmacol; 2020 May; 177(9):2024-2041. PubMed ID: 31883395
[TBL] [Abstract][Full Text] [Related]
4. Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.
Mäenpää N; Tiainen L; Hämäläinen M; Luukkaala T; Tanner M; Lahdenperä O; Vihinen P; Karihtala P; Kellokumpu-Lehtinen PL; Moilanen E; Jukkola A
BMC Cancer; 2024 Mar; 24(1):331. PubMed ID: 38468231
[TBL] [Abstract][Full Text] [Related]
5. Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.
Pagani E; Ruffini F; Antonini Cappellini GC; Scoppola A; Fortes C; Marchetti P; Graziani G; D'Atri S; Lacal PM
Int J Oncol; 2016 Apr; 48(4):1581-9. PubMed ID: 26846845
[TBL] [Abstract][Full Text] [Related]
6. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
[TBL] [Abstract][Full Text] [Related]
7. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer.
Lu R; Zhang J; Zhang W; Huang Y; Wang N; Zhang Q; Qu S
Cancer Biomark; 2018; 22(2):249-256. PubMed ID: 29630518
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
11. FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer.
Xie Q; Xiao YS; Jia SC; Zheng JX; Du ZC; Chen YC; Chen MT; Liang YK; Lin HY; Zeng D
Cancer Cell Int; 2020 Nov; 20(1):562. PubMed ID: 33292226
[TBL] [Abstract][Full Text] [Related]
12. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
Bagegni NA; Tao Y; Ademuyiwa FO
PLoS One; 2019; 14(9):e0222358. PubMed ID: 31536530
[TBL] [Abstract][Full Text] [Related]
14. Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery.
Verma C; Kaewkangsadan V; Eremin JM; Cowley GP; Ilyas M; El-Sheemy MA; Eremin O
J Transl Med; 2015 Jun; 13():180. PubMed ID: 26040463
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatics analysis and clinical significance of NRP-1 in triple-negative breast cancer.
Ma X; Liu H; Shi C; Zhao Y; Wang H; Han Z
Heliyon; 2024 Mar; 10(5):e27368. PubMed ID: 38495206
[TBL] [Abstract][Full Text] [Related]
16. Refining the indications for neoadjuvant chemotherapy for patients with HER2+ breast cancer: A single institution experience.
Pomponio MK; Burkbauer L; Goldbach M; Nazarian SM; Xie F; Clark AS; Matro JM; Fox KR; Shulman LN; Keele LJ; Tchou J
J Surg Oncol; 2020 Mar; 121(3):447-455. PubMed ID: 31919848
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
18. A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy.
Chen Y; Cai H; Chen W; Guan Q; He J; Guo Z; Li J
Front Mol Biosci; 2020; 7():34. PubMed ID: 32269999
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression.
Frères P; Josse C; Bovy N; Boukerroucha M; Struman I; Bours V; Jerusalem G
J Cell Physiol; 2015 Feb; 230(2):473-81. PubMed ID: 25078559
[TBL] [Abstract][Full Text] [Related]
20. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
Alves WEFM; Bonatelli M; Dufloth R; Kerr LM; Carrara GFA; da Costa RFA; Scapulatempo-Neto C; Tiezzi D; da Costa Vieira RA; Pinheiro C
BMC Cancer; 2019 Dec; 19(1):1173. PubMed ID: 31795962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
